Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003328 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00003328 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 600 participants.
The verdict
NCT00003328, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy followed by porfiromycin is more effective than radiation therapy alone in treating patients with head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of radiation therapy followed by porfiromycin in treating patients with stage III or stage IV head and neck cancer.
Interventions
- RADIATION radiation therapy
- DRUG porfiromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 1997-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003328
The ClinicalTrials.gov registry entry for NCT00003328 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00003328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003328 about?
NCT00003328 is a clinical study titled "Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy followed by porfiromycin is more effective than radiation therapy alo...
What is the current status of trial NCT00003328?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 1997-12.
What interventions are being tested in trial NCT00003328?
The interventions under investigation include: radiation therapy (RADIATION), porfiromycin (DRUG).
Who is sponsoring clinical trial NCT00003328?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.